Johnson & Johnson at peer perform by Bear Stearns

Bear Stearns analyst Rick Wise kept Johnson & Johnson at peer perform as the company prepares to enter the $1.5 billion HIV market with the expected approval of Prezista (TMC114) as second-line therapy in treatment-resistant patients. The analyst anticipates a third-quarter launch with $25 million in sales in 2006, $181 million in sales in 2007 and more than $700 million by 2010. Shares of the New Brunswick, N.J.-based pharmaceutical company were up 26 cents, or 0.42%, at $61.79 on volume of 6,997,300 shares versus the three-month running average of 8,701,000 shares. (NYSE: JNJ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.